Stenocare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Stenocare şirketinin toplam hissedar öz sermayesi DKK18.8M ve toplam borcu DKK2.8M olup, bu da borç-öz sermaye oranını 14.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK26.3M ve DKK7.4M dir.

Anahtar bilgiler

14.9%

Borç/özkaynak oranı

DKK 2.80m

Borç

Faiz karşılama oranı	n/a
Nakit	DKK 52.38k
Eşitlik	DKK 18.84m
Toplam yükümlülükler	DKK 7.43m
Toplam varlıklar	DKK 26.27m

Son finansal sağlık güncellemeleri

Recent updates

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Mar 29

We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

Nov 29

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Apr 02

Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: STENO 'nin kısa vadeli varlıkları ( DKK5.5M ) kısa vadeli yükümlülüklerini ( DKK4.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: STENO şirketinin kısa vadeli varlıkları ( DKK5.5M ) uzun vadeli yükümlülüklerini ( DKK2.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: STENO 'nin net borç/öz sermaye oranı ( 14.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: STENO 'nin borç/öz sermaye oranı son 5 yılda 92.8% seviyesinden 14.9% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: STENO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 2 oranında tarihsel oranda büyümeye devam ederse STENO un bir yıldan az nakit akışı süresi vardır.

Stenocare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?

Stenocare A/S (Denmark) to Be from Other OTC

Recent updates

Insufficient new directors

Third quarter 2024 earnings released

Stenocare A/S to Report Q1, 2025 Results on May 08, 2025

Stenocare A/S Announces Resignation of Søren Kjær as Board Member

Stenocare A/S Updates Earnings Guidance for the Year 2024

Second quarter 2024 earnings released

Stenocare A/S Updates Sales Guidance for the Year 2024

Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in Australia

First quarter 2024 earnings released

Stenocare A/S to Report Fiscal Year 2024 Results on Feb 27, 2025

Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark

Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients

New major risk - Share price stability

STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in Denmark

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.1.40 loss in FY 2022)

Stenocare A/S to Report Q1, 2024 Results on May 02, 2024

New major risk - Shareholder dilution

Stenocare A/S Expands Presence with New Medical Cannabis Oil Product

Third quarter 2023 earnings released

Stenocare Ready to Ship Medical Cannabis to German Patients

Second quarter 2023 earnings released

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare A/S Provides Update on Their Strong Danish Product Pipeline

First quarter 2023 earnings released

New minor risk - Shareholder dilution

Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis Product

Stenocare A/S Launches IT-Platform for Online Clinics

Full year 2022 earnings released

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare's New STENOCARE CBD Medical Cannabis Oil Product Is Available in Denmark

Less than half of directors are independent

Stenocare A/S Reaffirms Sales Guidance for the Fourth Quarter of 2022 and Provides Sales Guidance for the Year 2023

Third quarter 2022 earnings released

Stenocare A/S Receives Approval from the Danish Medicines Agency to Sell New Cbd Medical Cannabis Oil Product to Danish Patients

Stenocare A/S Announces Results from New Medical Cannabis Oil Study

Second quarter 2022 earnings released

First quarter 2022 earnings released

Less than half of directors are independent

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Stenocare A/S and Solural Pharma Announce Positive Outcome of Feasibility Study

Stenocare A/S Approves to Supply Danish Patients with Medical Cannabis Oil Products

We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

First quarter 2021 earnings released

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

More Choice for Treatment of Swedish Patients with Medical Cannabis Oil

Emerald Health Therapeutics, Inc. Announces That Its Partner, Stenocare A/S, Completed Its First Shipment and Delivery of Emerald Medical Cannabis Oil

STENOCARE A/S and Emerald Health Therapeutics Inc Announces First Shipment and Delivery of Medical Cannabis Oil

New 90-day high: kr.18.24

Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?

Stenocare A/S to Report Q1, 2021 Results on May 06, 2021

Stenocare A/S to Report Q2, 2021 Results on Aug 19, 2021

New 90-day low: kr.15.16

New 90-day low: kr.16.30

Stenocare A/S (Denmark) to Be from Other OTC

Stenocare A/S to Report Fiscal Year 2020 Results on Feb 25, 2021

Earnings released

Stenocare A/S to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low - kr.17.06

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin